FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGE</b>	ES IN BENE	FICIAL O	WNERSHI	Ρ

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average bi	urden								

hours per response:

0.5

	Check this box if no longer subject to
ì	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  STAAB THOMAS R II			<u>I</u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200				1	3. Date of Earliest Transaction (Month/Day/Year) 12/17/2019					X	below) `` Senior	Vice Presi	below) dent and CF	D	
(Street)  DURHA			27703	4	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Ind Line)						
(City)	(S	itate)	(Zip) able I - Non-D				•				. 6	<u> </u>			
1. Title of Security (Instr. 3)  2. Tran Date (Month)  Table II - Deriva			Transact te onth/Day	Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  2A. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)		Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Ownership orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa	nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		d Amount les g Security nd 4)	8. Price of Derivative Security (Instr. 5)		Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares				
Emp. Stock Option (Right to Buy)	\$3.23	12/17/2019		A		165,000 <sup>(1)</sup>		12/17/2020	12/17/2029	Common Stock	165,000	\$0	165,000	D	

## **Explanation of Responses:**

1. Annual Employee option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of attorney 12/19/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.